KORU Medical Systems, Inc. - 8-K Summary
Business Context and Reporting Period
KORU Medical Systems, Inc. (KRMD) filed a Current Report on Form 8-K on August 5, 2026. The filing announces financial results for the second fiscal quarter ended June 30, 2026, and provides an update to financial guidance for the fiscal year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results were released in a press release (Exhibit 99.1) and discussed in a conference call.
The Company utilizes the following non-GAAP financial measures to supplement GAAP results:
- Adjusted EBITDA: Defined as net income/loss before depreciation and amortization, interest (income) net, litigation expense, and stock-based compensation expense.
- Adjusted Diluted EPS: Derived from reported diluted EPS by excluding depreciation and amortization, interest (income) net, litigation expense, and stock-based compensation expense.
Material Changes and Guidance
The Company updated its financial guidance for the fiscal year ended December 31, 2025. Specific details regarding the magnitude or direction of these changes are not contained within the 8-K text itself but are referenced in the attached press release.
Management Commentary and Risks
Management states that non-GAAP measures are used to enhance investor understanding of ongoing operational performance and to facilitate comparisons between periods. The Company cautions that these measures may differ from similar metrics used by other companies and should not be considered replacements for GAAP measures. A reconciliation of GAAP to non-GAAP results is provided in Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net income, and cash flow figures.
- Verify the specific details of the updated fiscal year 2025 guidance.
- Examine the reconciliation table in the press release to understand the adjustments made to reach Adjusted EBITDA and Adjusted Diluted EPS.
- Confirm the impact of litigation expenses and stock-based compensation on the reported results.